Inclusion criteria | Exclusion criteria |
---|---|
Age 6 months to < 18 years | Planned urological surgery expected to influence kidney function or scheduled renal transplant within the study time frame |
 | Systemic hypertension (stage 2 as defined by the institutional guidelines on BP management |
Systemic hypotension defined as symptomatic hypotension or a mean systolic BP below the 5th percentile for age, sex, and height but no lower than 80 mmHg for participants < 18 years and symptomatic hypotension or a mean SBP < 90 mmHg in participants ≥ 18 years at visit 1 | |
CKD stages 1–3a (eGFR ≥ 30 mL/min/1.73 m2) for children aged ≥ 1 year to < 18 years or serum creatinineb ≤ 0.40 mg/dL for infants aged 6 months to < 1 year | Children with hemolytic uremic syndrome diagnosed ≤ 6 months prior to screening |
Participants on high dose glucocorticoids, cyclophosphamide, or biological therapies (rituximab and abatacept) within < 6 months prior to screening | |
Proteinuria defined as UPCR of ≥ 0.50 g/g in patients aged ≥ 2 years with CKD stage 2 or 3, or UPCR ≥ 1.0 g/g for patients aged < 2 years or ≥ 2 years with CKD stage 1 | Patients with nephrotic syndrome receiving albumin infusions or with acute kidney injury requiring dialysis within the last 6 months prior to screening |
On a maximum tolerated dose of RAASi | Concomitant therapy with an MRA, renin inhibitor, SGLT2i, ARNI, or potassium-sparing diuretic within 30Â days prior to screening |
Serum [K+] ≤ 5.0 mmol/L for children ≥ 2 years old and ≤ 5.3 mmol/L for children < 2 years old | Concomitant therapy with both ACEi and ARBs together |
Concomitant therapy with strong CYP3A4 inhibitors, or moderate or strong CYP3A4 inducers within 7Â days prior to randomization |